SARS-CoV-2 mRNA vaccination should start three months after bone marrow transplant, study suggests

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network, and Fred Hutchinson Cancer Center. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.
2025 Dr. Eddie Méndez Scholar Award Recipients, top row left to right: Caitlin Cornell, PhD, Elizabeth Kaweesa, PhD, Leandro Fernández-García, PhD, Almudena Chaves Pérez, PhD. Bottom row left to right: Luis Cedeño-Rosario, PhD, Nicole Halmai, PhD, Megan E. Meuser, PhD, Sarah Elisabeth Pierce, PhD.  Fred Hutch Cancer Center has announced eight recipients of the 2025 Dr. Eddie Méndez Scholar Award. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login